MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeutically

Enkhtsetseg Munkhbaatar(TUM Klinikum), Philipp J. Jost(Medical University of Graz), Stefan Fröhling(German Cancer Research Center), Rickmer Braren(TUM Klinikum), Charles Swanton(The Francis Crick Institute), Caterina Branca(University of Utah), Wilko Weichert(Deutsches Konsortium für Translationale Krebsforschung), Mathias Heikenwälder(University of Tübingen), Franz Pfeiffer(Technical University of Munich), Moritz Jesinghaus(Philipps University of Marburg), Irina Heid(TUM Klinikum), Georgios T. Stathopoulos(University of Nicosia), Pidassa Bidola(Technical University of Munich), Sebastian Lange(TUM Klinikum), Martijn van Griensven(Mayo Clinic), Ulrike Höckendorf(TUM Klinikum), Andreas Strasser(The University of Melbourne), Anna-Lena Meinhardt(TUM Klinikum), Ritu Mishra(TUM Klinikum), Nicole Pfarr(Technical University of Munich), Nicholas McGranahan(CRUK Lung Cancer Centre of Excellence), Florian Bassermann(TUM Klinikum), Deepti Agrawal(TUM Klinikum), Jürgen Ruland(Technical University of Munich), Michelle Dietzen(Cancer Research UK), Julia Slotta‐Huspenina(Technical University of Munich), Μάγδα Σπέλλα(University of Patras), Adam Wahida(National Center for Tumor Diseases), Roland Rad(ING Direct), Martina Anton(Technical University of Munich), Thomas Muley(German Center for Lung Research), Patrina S. P. Poh(Berlin Institute of Health at Charité - Universitätsmedizin Berlin), Sebastian Uhrig(German Cancer Research Center), Xin Wang(Nanjing Medical University), Katja Steiger(Technical University of Munich), Arne Warth(Heidelberg University), Melanie Boxberg(Starnberg Hospital)
Nature Communications
September 10, 2020
Cited by 62


Related Papers